<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01356355</url>
  </required_header>
  <id_info>
    <org_study_id>ACE/HMP-02</org_study_id>
    <nct_id>NCT01356355</nct_id>
  </id_info>
  <brief_title>Study of Herbmed Plus in Ureteral Stent Discomfort</brief_title>
  <official_title>Double Blind Exploratory Three Arm Randomized Trial to Evaluate the Safety and Efficacy of Herbal Preparation 'Herbmed Plus' in Ureteral Stent Discomfort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr .S.B.PATANKAR</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amai Charitable Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of the Ayurvedic formulation
      ,Herbmed Plus against placebo and anti-cholinergic drugs in relieving the ureteral stent
      discomfort.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To evaluate the tolerability of ayurvedic preparation, Herbmed Plus in management of
           ureteral stent discomfort

        -  To know whether the ayurvedic preparation Herbmed Plus ,can reduce the requirement of
           analgesics or not

        -  To know whether the ayurvedic preparation ,Herbmed Plus can replace the use of
           analgesics/ anti cholinergics in relieving ureteral stent discomfort ?
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparative study for Safety , Efficacy of Herbmed plus and tolterodine in management of ureteral stent discomfort.</measure>
    <time_frame>3weeks to 3 months</time_frame>
    <description>-To compare the efficacy and safety of the Herbmed plus against placebo and anti-cholinergic drugs in relieving the ureteral stent discomfort viz.Dysuria, Urgency Frequency,Haematuria,Loin and suprapubic pain ,consumption of analgesics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of herbmed plus in management of ureteral stent discomfort</measure>
    <time_frame>3 weeks to 3 months</time_frame>
    <description>To evaluate the tolerability of Herbmed Plus in management of ureteral stent discomfort
To know whether the Herbmed Plus can reduce the requirement of analgesics or not
To know whether the Herbmed Plus can replace the use of analgesics/ anti cholinergics in relieving ureteral stent discomfort ?</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Ureteral Stent Discomfort</condition>
  <arm_group>
    <arm_group_label>Herbmed plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One capsule twice a day daily till ureteral stent in situ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One capsule twice a day daily till ureteral stent in situ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tolterodine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One capsule twice a day daily till ureteral stent in situ</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herbmed plus</intervention_name>
    <description>one capsule of herbmed plus orally twice a day with meals till the ureteral stent is in situ.</description>
    <arm_group_label>Herbmed plus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One capsule twice a day daily till ureteral stent in situ</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pills manufactured to mimic Herbmed plus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolterodine</intervention_name>
    <description>One capsule twice a day daily till ureteral stent in situ</description>
    <arm_group_label>Tolterodine</arm_group_label>
    <other_name>Torq SR</other_name>
    <other_name>Terol LA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:The following patients would be enrolled in the study:

          1. Age 18-75 years (Both inclusive)

          2. Absence of urinary tract infection

          3. Absence of lower urinary tract symptoms

          4. Absence of urethral catheter

          5. Patients with unilateral/bilateral ureteral stentSize of the stent ranging from 4/16
             to 6/26.

          6. Patients of reproductive potential (males and females) and willing to use a reliable
             means of contraception (e.g. hormonal contraceptive patch, intrauterine device and
             physical barrier) throughout study participation.

        7Able and willing to give written informed consent and comply with the requirements of the
        study protocol

        Exclusion Criteria:

          1. Patients having evidence of urinary tract infection.

          2. Chronic medication with Î±-blockers or anticholinergics and severe complications during
             the procedure

          3. Uncontrolled diabetes, hypertension, symptomatic congestive heart failure, unstable
             angina pectoris, myocardial infarction.

          4. Any other urogenital disorders.

          5. Liver dysfunction, defined as total bilirubin &gt;1.5 x the upper limit of Normal
             (ULN),Aspartate aminotransferase (AST/SGOT) &gt; 2.5 x ULN, or alanine aminotransferase
             (ALT/SGPT) &gt;2.5 x ULN.

          6. Kidney disease, including serum creatinine level &gt;1.5 x ULN.

          7. Subjects on herbal supplements (plant extracts preparations or herbal medicines etc.)
             within previous 3 months.

          8. Participated in another clinical drug trial within 3 months before recruitment.

          9. Pregnancy or breast feeding.

         10. Evidence of significant uncontrolled concomitant disease which in the Investigator's
             opinion would preclude patient participation.

         11. Currently active alcohol or drug abuse or history of alcohol or drug abuse within 24
             weeks prior to baseline.

         12. Patients with psychiatric illness or other condition that would limit compliance with
             study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SURESH B PATANKAR, MS,MCH</last_name>
    <role>Principal Investigator</role>
    <affiliation>AMAI CHARITABLE TRUST (AMAI CHARITABLE TRUST'S ACE HOSPITAL PUNE)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AMAI Charitable Trust's ACE Hospital Pune</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Patankar S, Dobhada S, Bhansali M, Khaladkar S, Modi J. A prospective, randomized, controlled study to evaluate the efficacy and tolerability of Ayurvedic formulation &quot;varuna and banana stem&quot; in the management of urinary stones. J Altern Complement Med. 2008 Dec;14(10):1287-90. doi: 10.1089/acm.2008.0189.</citation>
    <PMID>19040391</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2011</study_first_submitted>
  <study_first_submitted_qc>May 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2011</study_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Amai Charitable Trust</investigator_affiliation>
    <investigator_full_name>Dr .S.B.PATANKAR</investigator_full_name>
    <investigator_title>Amai Charitable Trust,ACE Hospital Pune</investigator_title>
  </responsible_party>
  <keyword>Stent discomfort</keyword>
  <keyword>Herbmed plus</keyword>
  <keyword>Tolterodine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolterodine Tartrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

